Erratum: Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant-ineligible patients with multiple myeloma: a meta-analysis

被引：0
|
作者：
P Kapoor
S V Rajkumar
A Dispenzieri
M A Gertz
M Q Lacy
D Dingli
J R Mikhael
V Roy
R A Kyle
P R Greipp
S Kumar
S J Mandrekar
机构：
来源：
Leukemia | 2011年 / 25卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Correction to: Leukemia (2011) 4, 689–696; doi:10.1038/leu.2010.313; published online 14 January 2011 Since the publication of the above paper, the authors have noticed an error in Table 1. The number of MP and MPT patients in ‘IFM 01-01’ are 116 and 113, respectively; thus, the total number of patients listed should be 229 and not 226.
引用
收藏
页码：1523 / 1524
页数：1
相关论文
共 50 条
  • [21] Randomized comparison of dexamethasone combined with melphalan versus melphalan with prednisone in the treatment of elderly patients with multiple myeloma
    Hernández, JM
    García-Sanz, R
    Golvano, E
    Bladé, J
    Fernandez-Calvo, J
    Trujillo, J
    Soler, JA
    Gardella, S
    Carbonell, F
    Mateo, G
    San Miguel, JF
    BRITISH JOURNAL OF HAEMATOLOGY, 2004, 127 (02) : 159 - 164
  • [22] Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Alcyone Study
    Mateos, Maria-Victoria
    San-Miguel, Jesus
    Cavo, Michele
    Creixenti, Joan Blade
    Suzuki, Kenshi
    Jakubowiak, Andrzej
    Knop, Stefan
    Doyen, Chantal
    Lucio, Paulo
    Nagy, Zsolt
    Pour, Ludek
    Grosicki, Sebastian
    Crepaldi, Andre H.
    Liberati, Anna Marina
    Campbell, Philip
    Shelekhova, Tatiana
    Yoon, Sung-Soo
    Iosava, Genadi
    Fujisaki, Tomoaki
    Garg, Mamta
    Pei, Huiling
    Krevvata, Maria
    Carson, Robin
    Borgsten, Fredrik
    Dimopoulos, Meletios A.
    BLOOD, 2022, 140 : 10157 - 10159
  • [23] Melphalan plus Prednisone Versus Melphalan plus Prednisone plus Thalidomide in Induction Therapy for Multiple Myeloma in Elderly Patients: Final Analysis of the Dutch Cooperative Group HOVON 49 Study
    Wijermans, P.
    Schaafsma, M.
    van Norden, Y.
    Ammerlaan, R.
    Wittebol, S.
    Sinnige, H.
    Zweegman, Sonja
    Kooi, M. van Marwijk
    Van der Griend, R.
    Lokhorst, H.
    Sonneveld, P.
    BLOOD, 2008, 112 (11) : 241 - 242
  • [24] Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myeloma
    Palumbo, A.
    Davies, F.
    Kropff, M.
    Blade, J.
    Delforge, M.
    da Costa, F. Leal
    Garcia Sanz, R.
    Schey, S.
    Facon, T.
    Morgan, G.
    Moreau, P.
    ANNALS OF HEMATOLOGY, 2010, 89 (08) : 803 - 811
  • [25] Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myeloma
    A. Palumbo
    F. Davies
    M. Kropff
    J. Bladé
    M. Delforge
    F. Leal da Costa
    R. Garcia Sanz
    S. Schey
    T. Facon
    G. Morgan
    P. Moreau
    Annals of Hematology, 2010, 89 : 803 - 811
  • [26] Melphalan, prednisone, thalidomide and defibrotide in advanced myeloma
    Palumbo, A.
    Gay, F.
    Rus, C.
    Pregno, P.
    Larocca, A.
    Bringhen, S.
    Magarotto, V.
    D'Agostino, F.
    Iacobelli, M.
    Gaidano, G.
    Mitsiades, C.
    Richardson, P. G.
    Anderson, K. C.
    Boccadoro, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 169 - 169
  • [27] Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma
    Palumbo, A
    Avonto, I
    Bruno, B
    Ambrosini, MT
    Bringhen, S
    Cavallo, F
    Falco, P
    Boccadoro, M
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2006, 76 (04) : 273 - 277
  • [28] Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial
    Mateos, Maria-Victoria
    Oriol, Albert
    Martinez-Lopez, Joaquin
    Gutierrez, Norma
    Teruel, Ana-Isabel
    de Paz, Raquel
    Garcia-Larana, Jose
    Bengoechea, Enrique
    Martin, Alejandro
    Diaz Mediavilla, Joaquin
    Palomera, Luis
    de Arriba, Felipe
    Gonzalez, Yolanda
    Hernandez, Jose-Mariano
    Sureda, Ana
    Bello, Jose-Luis
    Bargay, Joan
    Penalver, Francisco-Javier
    Ribera, Jose-Maria
    Martin-Mateos, Maria-Luisa
    Garcia-Sanz, Ramon
    Cibeira, Maria-Teresa
    Martin Ramos, Maria-Luisa
    Vidriales, Maria-Belen
    Paiva, Bruno
    Montalban, Maria-Angeles
    Lahuerta, Juan-Jose
    Blade, Joan
    San Miguel, Jesus-Fernando
    LANCET ONCOLOGY, 2010, 11 (10): : 934 - 941
  • [29] Melphalan, prednisone and thalidomide in newly diagnosed myeloma
    Palumbo, A.
    Bringhen, S.
    Caravita, T.
    Falcone, A.
    Callea, V.
    Petrucci, M. T.
    Morandi, S.
    Capaldi, A.
    Lauta, V. M.
    Pisani, F.
    Zambello, R.
    Pregno, P.
    Magarotto, V.
    Avonto, I.
    Musto, P.
    Liberati, A. M.
    Boccadoro, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 176 - 176
  • [30] Indirect Comparison of the Efficacy of Melphalan-Prednisone-Bortezomib Relative to Melphalan-Prednisone-Thalidomide and Melphalan-Prednisone for the First Line Treatment of Multiple Myeloma
    Yeh, Yating
    Chambers, James
    Gaugris, Sabine
    Jansen, Jeroen
    BLOOD, 2008, 112 (11) : 825 - 825
12345